Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021

Upgrades

• Janney Montgomery Scott upgraded the previous rating for Centerspace CSR from Neutral to Buy. In the first quarter, Centerspace showed an EPS of $0.95, compared to $0.90 from the year-ago quarter. The current stock performance of Centerspace shows a 52-week-high of $74.00 and a 52-week-low of $66.91. Moreover, at the end of the last trading period, the closing price was at $69.89.
• For MediaAlpha Inc MAX, Citigroup upgraded the previous rating of Neutral to Buy. MediaAlpha earned $0.00 in the first quarter. At the moment, the stock has a 52-week-high of $70.33 and a 52-week-low of $32.04. MediaAlpha closed at $37.11 at the end of the last trading period.
• According to Rosenblatt, the prior rating for Snowflake Inc SNOW was changed from Neutral to Buy. In the fourth quarter, Snowflake earned $0.16. At the moment, the stock has a 52-week-high of $429.00 and a 52-week-low of $184.71. Snowflake closed at $212.65 at the end of the last trading period.
• For Cerence Inc CRNC, Evercore ISI Group upgraded the previous rating of In-Line to Outperform. Cerence earned $0.69 in the second quarter, compared to $0.43 in the year-ago quarter. The current stock performance of Cerence shows a 52-week-high of $139.00 and a 52-week-low of $24.44. Moreover, at the end of the last trading period, the closing price was at $83.33.
• Credit Suisse upgraded the previous rating for Gap Inc GPS from Underperform to Neutral. For the fourth quarter, Gap had an EPS of $0.28, compared to year-ago quarter EPS of $0.58. The current stock performance of Gap shows a 52-week-high of $37.05 and a 52-week-low of $6.92. Moreover, at the end of the last trading period, the closing price was at $36.33.
• Mizuho upgraded the previous rating for Alliant Energy Corp LNT from Neutral to Buy. For the first quarter, Alliant Energy had an EPS of $0.68, compared to year-ago quarter EPS of $0.72. The stock has a 52-week-high of $58.19 and a 52-week-low of $44.74. At the end of the last trading period, Alliant Energy closed at $56.48.
• According to Raymond James, the prior rating for Palo Alto Networks Inc PANW was changed from Market Perform to Outperform. In the second quarter, Palo Alto Networks showed an EPS of $1.55, compared to $1.19 from the year-ago quarter. The stock has a 52-week-high of $403.00 and a 52-week-low of $216.95. At the end of the last trading period, Palo Alto Networks closed at $335.80.
• For Mastercard Inc MA, Daiwa Capital upgraded the previous rating of Neutral to Outperform. Mastercard earned $1.74 in the first quarter, compared to $1.83 in the year-ago quarter. The current stock performance of Mastercard shows a 52-week-high of $401.50 and a 52-week-low of $273.29. Moreover, at the end of the last trading period, the closing price was at $363.30.
• For Visa Inc V, Daiwa Capital upgraded the previous rating of Neutral to Outperform. In the second quarter, Visa showed an EPS of $1.38, compared to $1.39 from the year-ago quarter. At the moment, the stock has a 52-week-high of $237.50 and a 52-week-low of $178.87. Visa closed at $226.44 at the end of the last trading period.
• JP Morgan upgraded the previous rating for MGM Resorts International MGM from Neutral to Overweight. In the first quarter, MGM Resorts Intl showed an EPS of $0.68, compared to $0.45 from the year-ago quarter. The current stock performance of MGM Resorts Intl shows a 52-week-high of $42.74 and a 52-week-low of $13.20. Moreover, at the end of the last trading period, the closing price was at $38.75.

See all analyst ratings upgrades.

Downgrades

• Barclays downgraded the previous rating for II-VI Inc IIVI from Overweight to Equal-Weight. In the third quarter, II-VI showed an EPS of $0.91, compared to $0.47 from the year-ago quarter. At the moment, the stock has a 52-week-high of $100.44 and a 52-week-low of $36.04. II-VI closed at $63.57 at the end of the last trading period.
• According to Goldman Sachs, the prior rating for Adtran Inc ADTN was changed from Buy to Neutral. For the first quarter, Adtran had an EPS of $0.13, compared to year-ago quarter EPS of $0.05. At the moment, the stock has a 52-week-high of $20.49 and a 52-week-low of $9.66. Adtran closed at $20.21 at the end of the last trading period.

See all analyst ratings downgrades.

Initiations

• With a Buy rating, Tudor Pickering initiated coverage on General Motors Co GM. The price target seems to have been set at $76.00 for General Motors. General Motors earned $2.25 in the first quarter, compared to $0.62 in the year-ago quarter. The stock has a 52-week-high of $63.44 and a 52-week-low of $21.83. At the end of the last trading period, General Motors closed at $56.04.
• Tudor Pickering initiated coverage on Ford Motor Co F with a Buy rating. The price target for Ford Motor is set to $17.00. In the first quarter, Ford Motor showed an EPS of $0.89, compared to $0.23 from the year-ago quarter. The current stock performance of Ford Motor shows a 52-week-high of $13.62 and a 52-week-low of $4.75. Moreover, at the end of the last trading period, the closing price was at $12.15.
• Keybanc initiated coverage on Latham Group Inc SWIM with an Overweight rating. The price target for Latham Group is set to $38.00. The stock has a 52-week-high of $33.26 and a 52-week-low of $23.58. At the end of the last trading period, Latham Group closed at $32.70.
• With a Buy rating, Guggenheim initiated coverage on Rain Therapeutics Inc RAIN. The price target seems to have been set at $26.00 for Rain Therapeutics. The stock has a 52-week-high of $23.90 and a 52-week-low of $14.08. At the end of the last trading period, Rain Therapeutics closed at $15.97.
• With a Buy rating, Citigroup initiated coverage on Agiliti Inc AGTI. The price target seems to have been set at $19.00 for Agiliti. The stock has a 52-week-high of $17.08 and a 52-week-low of $13.56. At the end of the last trading period, Agiliti closed at $14.73.
• Guggenheim initiated coverage on Impel NeuroPharma Inc IMPL with a Buy rating. The price target for Impel NeuroPharma is set to $32.00. The stock has a 52-week-high of $15.89 and a 52-week-low of $13.46. At the end of the last trading period, Impel NeuroPharma closed at $13.89.
• Citigroup initiated coverage on KnowBe4 Inc KNBE with a Neutral rating. The price target for KnowBe4 is set to $21.00. At the moment, the stock has a 52-week-high of $26.98 and a 52-week-low of $17.10. KnowBe4 closed at $19.10 at the end of the last trading period.
• With a Buy rating, Benchmark initiated coverage on TS Innovation Acquisitions Corp TSIA. The price target seems to have been set at $16.00 for TS Innovation. At the moment, the stock has a 52-week-high of $19.70 and a 52-week-low of $9.86. TS Innovation closed at $9.97 at the end of the last trading period.
• JonesTrading initiated coverage on aTyr Pharma Inc LIFE with a Buy rating. The price target for aTyr Pharma is set to $15.00. aTyr Pharma earned $0.51 in the first quarter, compared to $0.25 in the year-ago quarter. At the moment, the stock has a 52-week-high of $8.33 and a 52-week-low of $2.93. aTyr Pharma closed at $3.66 at the end of the last trading period.
• With an Outperform rating, Wedbush initiated coverage on Impel NeuroPharma Inc IMPL. The price target seems to have been set at $21.00 for Impel NeuroPharma. The stock has a 52-week-high of $15.89 and a 52-week-low of $13.46. At the end of the last trading period, Impel NeuroPharma closed at $13.89.
• With an Overweight rating, JP Morgan initiated coverage on Treace Medical Concepts Inc TMCI. The price target seems to have been set at $37.00 for Treace Medical Concepts. The current stock performance of Treace Medical Concepts shows a 52-week-high of $34.47 and a 52-week-low of $24.25. Moreover, at the end of the last trading period, the closing price was at $29.36.
• With a Neutral rating, UBS initiated coverage on Agiliti Inc AGTI. The price target seems to have been set at $16.00 for Agiliti. The stock has a 52-week-high of $17.08 and a 52-week-low of $13.56. At the end of the last trading period, Agiliti closed at $14.73.
• With a Buy rating, BTIG initiated coverage on Surface Oncology Inc SURF. The price target seems to have been set at $17.00 for Surface Oncology. Surface Oncology earned $0.37 in the first quarter, compared to $0.74 in the year-ago quarter. The current stock performance of Surface Oncology shows a 52-week-high of $14.40 and a 52-week-low of $2.58. Moreover, at the end of the last trading period, the closing price was at $8.46.
• With a Buy rating, BTIG initiated coverage on Poseida Therapeutics Inc PSTX. The price target seems to have been set at $40.00 for Poseida Therapeutics. Poseida Therapeutics earned $0.62 in the first quarter. The current stock performance of Poseida Therapeutics shows a 52-week-high of $15.79 and a 52-week-low of $7.63. Moreover, at the end of the last trading period, the closing price was at $8.84.
• With a Buy rating, BTIG initiated coverage on Mustang Bio Inc MBIO. The price target seems to have been set at $11.00 for Mustang Bio. In the first quarter, Mustang Bio showed an EPS of $0.19, compared to $0.28 from the year-ago quarter. The current stock performance of Mustang Bio shows a 52-week-high of $5.22 and a 52-week-low of $2.42. Moreover, at the end of the last trading period, the closing price was at $2.86.
• BTIG initiated coverage on CASI Pharmaceuticals Inc CASI with a Buy rating. The price target for CASI Pharmaceuticals is set to $4.00. CASI Pharmaceuticals earned $0.11 in the first quarter, compared to $0.09 in the year-ago quarter. The current stock performance of CASI Pharmaceuticals shows a 52-week-high of $3.90 and a 52-week-low of $1.32. Moreover, at the end of the last trading period, the closing price was at $1.44.
• B. Riley Securities initiated coverage on Magenta Therapeutics Inc MGTA with a Buy rating. The price target for Magenta Therapeutics is set to $21.00. Magenta Therapeutics earned $0.36 in the first quarter, compared to $0.51 in the year-ago quarter. The current stock performance of Magenta Therapeutics shows a 52-week-high of $14.20 and a 52-week-low of $6.03. Moreover, at the end of the last trading period, the closing price was at $10.40.
• Piper Sandler initiated coverage on Rain Therapeutics Inc RAIN with an Overweight rating. The price target for Rain Therapeutics is set to $25.00. The stock has a 52-week-high of $23.90 and a 52-week-low of $14.08. At the end of the last trading period, Rain Therapeutics closed at $15.97.
• Goldman Sachs initiated coverage on Rain Therapeutics Inc RAIN with a Buy rating. The price target for Rain Therapeutics is set to $56.00. At the moment, the stock has a 52-week-high of $23.90 and a 52-week-low of $14.08. Rain Therapeutics closed at $15.97 at the end of the last trading period.
• Goldman Sachs initiated coverage on Pool Corp POOL with a Buy rating. The price target for Pool is set to $535.00. In the first quarter, Pool showed an EPS of $2.42, compared to $0.71 from the year-ago quarter. The stock has a 52-week-high of $449.44 and a 52-week-low of $214.77. At the end of the last trading period, Pool closed at $435.67.
• With a Buy rating, Goldman Sachs initiated coverage on Arena Pharmaceuticals Inc ARNA. The price target seems to have been set at $90.00 for Arena Pharmaceuticals. For the first quarter, Arena Pharmaceuticals had an EPS of $1.98, compared to year-ago quarter EPS of $2.00. At the moment, the stock has a 52-week-high of $90.19 and a 52-week-low of $45.09. Arena Pharmaceuticals closed at $60.89 at the end of the last trading period.
• With a Neutral rating, Goldman Sachs initiated coverage on BioNTech SE BNTX. The price target seems to have been set at $173.00 for BioNTech. In the first quarter, BioNTech showed an EPS of $5.29, compared to $0.26 from the year-ago quarter. The current stock performance of BioNTech shows a 52-week-high of $213.15 and a 52-week-low of $46.30. Moreover, at the end of the last trading period, the closing price was at $198.30.
• With a Buy rating, Goldman Sachs initiated coverage on Revolution Medicines Inc RVMD. The price target seems to have been set at $49.00 for Revolution Medicines. Revolution Medicines earned $0.53 in the first quarter, compared to $0.74 in the year-ago quarter. At the moment, the stock has a 52-week-high of $56.18 and a 52-week-low of $21.17. Revolution Medicines closed at $31.48 at the end of the last trading period.
• With a Buy rating, Stifel initiated coverage on Treace Medical Concepts Inc TMCI. The price target seems to have been set at $35.00 for Treace Medical Concepts. The stock has a 52-week-high of $34.47 and a 52-week-low of $24.25. At the end of the last trading period, Treace Medical Concepts closed at $29.36.
• With a Neutral rating, UBS initiated coverage on Stoke Therapeutics Inc STOK. The price target seems to have been set at $35.00 for Stoke Therapeutics. In the first quarter, Stoke Therapeutics showed an EPS of $0.46, compared to $0.34 from the year-ago quarter. The current stock performance of Stoke Therapeutics shows a 52-week-high of $71.58 and a 52-week-low of $22.00. Moreover, at the end of the last trading period, the closing price was at $35.19.
• With a Buy rating, UBS initiated coverage on Denali Therapeutics Inc DNLI. The price target seems to have been set at $70.00 for Denali Therapeutics. In the first quarter, Denali Therapeutics showed an EPS of $0.58, compared to $0.55 from the year-ago quarter. At the moment, the stock has a 52-week-high of $93.94 and a 52-week-low of $21.41. Denali Therapeutics closed at $53.64 at the end of the last trading period.
• With a Buy rating, Guggenheim initiated coverage on Onconova Therapeutics Inc ONTX. The price target seems to have been set at $4.00 for Onconova Therapeutics. In the first quarter, Onconova Therapeutics showed an EPS of $0.02, compared to $0.03 from the year-ago quarter. The current stock performance of Onconova Therapeutics shows a 52-week-high of $1.93 and a 52-week-low of $0.19. Moreover, at the end of the last trading period, the closing price was at $0.62.
• With a Buy rating, HC Wainwright & Co. initiated coverage on Redhill Biopharma Ltd RDHL. The price target seems to have been set at $23.00 for Redhill Biopharma. In the fourth quarter, Redhill Biopharma showed an EPS of $0.07, compared to $0.03 from the year-ago quarter. The current stock performance of Redhill Biopharma shows a 52-week-high of $11.52 and a 52-week-low of $5.91. Moreover, at the end of the last trading period, the closing price was at $6.31.
• With a Buy rating, HC Wainwright & Co. initiated coverage on F-star Therapeutics Inc FSTX. The price target seems to have been set at $35.00 for F-star Therapeutics. In the first quarter, F-star Therapeutics earned $1.08. The stock has a 52-week-high of $15.50 and a 52-week-low of $6.26. At the end of the last trading period, F-star Therapeutics closed at $6.74.
• With a Buy rating, HC Wainwright & Co. initiated coverage on Allakos Inc ALLK. The price target seems to have been set at $230.00 for Allakos. In the first quarter, Allakos showed an EPS of $1.04, compared to $0.57 from the year-ago quarter. At the moment, the stock has a 52-week-high of $157.98 and a 52-week-low of $62.21. Allakos closed at $100.54 at the end of the last trading period.
• Needham initiated coverage on InMode Ltd INMD with a Buy rating. The price target for InMode is set to $94.00. InMode earned $0.69 in the first quarter, compared to $0.30 in the year-ago quarter. The current stock performance of InMode shows a 52-week-high of $92.38 and a 52-week-low of $23.00. Moreover, at the end of the last trading period, the closing price was at $74.73.
• Keybanc initiated coverage on Agiliti Inc AGTI with an Overweight rating. The price target for Agiliti is set to $21.00. The current stock performance of Agiliti shows a 52-week-high of $17.08 and a 52-week-low of $13.56. Moreover, at the end of the last trading period, the closing price was at $14.73.

See all analyst ratings initiations.